First Three Exits U.S. Pain Management Market

Sunao Manabe, the new chief executive of first-three, said on a conference call that the company had returned Movantik, a treatment drug for opioid-induced constipation, to AstraZeneca from October and ended the Inspirion Delivery Sciences license agreement for opioids Morpha Bond and Roxy Bond"Through these actions, the First Iii will exit the pain treatment business in the U.Smarket and focus on the oncology business." Sunao addedfirst-ever access to the U.Spainkiller market dates back to 2014, when the company agreed to buy some hydrocodone combination drugs from Charleston Laboratories for $650 millionHowever, the partnership was terminated in 2017 after the FDA rejected THE CL-108, the main project of cooperation between the two companiesin order to develop an ailment portfolio in the United States, first three companies at that time obtained inspirion's FDA-approved morphine reprieve morpha Bond marketing license in the United States, and named it RoxyBondIn 2015, First Three signed an agreement with AstraZeneca for Movantik, paying a $200 million advance payment for joint marketing rightsBut the drug's performance fell short, with AstraZeneca's sales figures showing that sales in the U.Swere just $70m in the first three quarters of this year, down 14 per cent from a year earlierit is unclear whether the change will have an impact on the U.Ssales force in the U.SBut warning notices issued in August showed that First Three American companies plan to cut 68 jobs in New Jersey from October 7, however, the First Three has not given up on the pain business in the Japanese marketIn April, The First Three launched Tarlige in Japan to treat peripheral nerve pain in a bid to challenge Pfizer's heavy bomb, LyricaIn September, the company launched a new generic drug for hydroxycodonel hydrochloride in Japan to continue treating cancer painabandoned the U.S pain management market, the first three to double their investment in oncology First Three Republic aStrapolis recently signed a cancer treatment agreement, AstraZeneca purchased $6.9 billion for the first three-third-in-one adtandra monophonic anti-Drutican (DS-8201), for HER2 expression cancer treatment The drug's application to treat metastatic breast cancer has just been approved by the FDA and will be finalized in the second quarter of 2020 first three are ambitious for the oncology business In February 2018, First Three said it would reorganize its U.S business team in preparation for the upcoming oncology product At the time, the company planned to lay off nearly 280 employees Pexidartinib, the first product of its oncology product line, was approved by the FDA in August for the treatment of adult patients with severe morbidity or functional limitations that are not suitable for surgical improvement of symptomatic tendon cytoma (TGCT) The drug is the first and only drug approved for TGCT.